日本基因组编辑市场规模、份额、趋势分析报告：按技术、交付方式、应用、最终用途、模式和细分市场预测，2025 年至 2033 年

日本基因组编辑市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，日本基因组编辑市场预计到2033年将达到14.5亿美元，2025年至2033年期间的复合年增长率为17.97%。

日本基因组编辑市场正经历强劲扩张，这得益于精准医疗、再生医学和农业生物技术投资的不断增加。对下一代疗法（尤其是基因治疗、罕见疾病治疗和个人化肿瘤治疗方案）的日益关注，推动了对 CRISPR-Cas9、TALEN 和碱基编辑等先进基因组编辑技术的需求。监管激励措施和政府支援措施（例如资助生物技术创新和简化临床核准流程）进一步推动了市场发展势头。

强大的学术和研究基础设施以及全球知名研究机构的存在，为创新和跨部门合作提供了支持。製药公司、生技新兴企业和教育联盟正日益加强合作，致力于将基因编辑领域的突破转化为可行的临床和商业应用。日本人口老化和慢性遗传病患疾病率的上升，迫切需要针对基因组的干预措施，从而推动了对安全、有效且可扩展的基因编辑平台的需求。

递送系统、精准标靶和降低脱靶风险的技术进步正在拓展基因组编辑的治疗应用。与数位工具和人工智慧主导的生物资讯平台的整合正在改善标靶发现，优化设计工作流程，并加速临床前开发。在农业和食品生物技术领域，基因编辑正被用于开发抗病产量作物，以满足国家粮食安全和永续性目标。

凭藉跨部门伙伴关係、活性化的研发活动以及扶持性政策框架，日本的基因组编辑市场有望在塑造精准生物技术的未来方面发挥主导作用。策略联盟、在地化生产以及不断增长的智慧财产权组合正在巩固日本作为治疗和非治疗应用领域基因组编辑创新关键枢纽的地位。

日本基因组编辑市场报告重点

• 从技术面来看，CRISPR/Cas9 将主导日本基因组编辑市场，2024 年的市场占有率将达到 44.14%。这项优势归功于 CRISPR/Cas9 在标靶基因组修饰方面的卓越效率、精准度和成本效益。 CRISPR/Cas9 在研究机构、生物技术新兴企业和製药公司中的广泛应用，反映了其加速功能基因组学研究、治疗方法开发和农业创新的能力。 CRISPR/Cas9 工具相对易于设计且扩充性，适用于体外和体内应用。
• 依递送方式划分，体内基因组编辑将在2024年占据50.63%的市场占有率，引领市场。这得益于基因治疗和再生医学领域投资的不断增长，尤其是在遗传疾病和癌症治疗领域。日本先进的医疗基础设施和对治癒性疗法的重视，推动了脂质奈米颗粒和腺结合病毒载体 (AAV) 等新型递送平台的开发，从而实现了更高效的体内基因转移。直接在患者体内编辑基因的能力具有变革性的潜力，并持续吸引临床试验活动和投资。
• 从应用角度来看，基因工程将在2024年创造最高收入，市场占有率达73.16%。该领域的成长得益于日本在疾病建模、治疗方法探索和功能基因组学研究方面的努力。基因工程在学术界和产业界被广泛用于开发客製化细胞株、建构模型生物以及推进基因治疗研发管线。基因工程在农业和水产养殖的精准育种中也扮演关键角色。
• 在生技新兴企业和研究机构中，外包基因组编辑服务正变得越来越普遍。合约服务提供者可以提供专业知识、基础设施和监管支持，帮助创新者加快产品上市速度并控制开发成本。日本强大的合约研究和製造组织生态系统为临床前、临床和商业化阶段的基因编辑提供支援。
• 从最终用途来看，生技和製药公司将主导日本基因组编辑市场，到2024年将占49.66%的份额。这些公司正在利用基因组编辑加速药物研发，开发基因和细胞疗法，并探索复杂疾病的新治疗方法。强大的研发开发平臺和不断增加的政府奖励使这些最终用户处于创新的前沿。与学术机构和全球生物技术公司的合作进一步巩固了他们的地位，使其成为基因组编辑技术商业性应用的核心参与者。
• 2025 年 1 月，Takara Bio USA Holdings 完成对加州 Curio Biosciences 公司的收购，将该公司的 Trekker 和 Seeker 空间生物学平台整合到美国单细胞体学产品组合中。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

• 市场展望
  • 母市场展望
  • 相关/附随市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 日本基因组编辑市场分析工具
  • 产业分析-波特五力分析
  • PESTEL分析
  • COVID-19影响分析

第四章日本基因组编辑市场：技术商业分析

• 技术细分仪表板
• 日本基因组编辑市场技术变迁分析
• 日本基因组编辑市场规模及趋势分析（分技术，2021-2033）
• CRISPR/Cas9
• TALEN/MegaTAL
• ZFN
• Meganucleases
• 其他的

第五章日本基因组编辑市场：交付方式的商业分析

• 配送方式细分仪表板
• 日本基因组编辑市场交付方式的波动分析
• 日本基因组编辑市场规模及趋势分析（以交付方式，2021-2033）
• 体外
• 体内

第六章日本基因组编辑市场：应用业务分析

• 应用程式细分仪表板
• 日本基因组编辑市场应用变化分析
• 日本基因组编辑市场规模及趋势分析（依应用，2021-2033）
• 基因工程
• 临床应用

第七章日本基因组编辑市场：模式商业分析

• 模式细分仪表板
• 日本基因组编辑市场的波动
• 日本基因组编辑市场规模及趋势分析（按模式，2021-2033）
• 合约
• 内部

第八章日本基因组编辑市场：最终用途估计与趋势分析

• 最终用途细分仪表板
• 日本基因组编辑市场最终用途趋势分析
• 日本基因组编辑市场规模与趋势分析（依最终用途，2021-2033 年）
• 生物技术和製药公司
• 学术研究所
• 合约研究组织

第九章 竞争态势

• 公司/竞争对手分类
• 战略地图
• 2024年企业市场分析
• 公司简介/上市公司
  • Merck KGaA
  • Takara Bio Inc.
  • Revvity, Inc.
  • Danaher Corporation
  • GenScript
  • New England Biolabs
  • Lonza
  • Thermo Fisher Scientific, Inc.
  • Charles River Laboratories
  • Eurofins Scientific

Japan Genome Editing Market Growth & Trends:

The Japan genome editing market size is projected to reach USD 1.45 billion by 2033, growing at a CAGR of 17.97% from 2025 to 2033, according to a new report by Grand View Research, Inc. The Japan genome editing market is witnessing robust expansion, propelled by increasing investment in precision medicine, regenerative therapies, and agricultural biotechnology. The growing focus on next-generation therapeutics, particularly gene therapies, rare disease treatments, and personalized oncology solutions, fuels demand for advanced genome editing technologies such as CRISPR-Cas9, TALENs, and base editors. Regulatory encouragement and supportive government initiatives, including funding for biotech innovation and streamlining of clinical approval processes, further accelerate market momentum.

A strong academic and research infrastructure and the presence of globally recognized institutions underpin innovation and collaboration across sectors. Pharmaceutical companies, biotech startups, and educational consortia are increasingly converging to translate gene editing breakthroughs into viable clinical and commercial applications. Japan's aging population and rising incidence of chronic genetic disorders are also driving urgency around genome-targeted interventions, catalyzing demand for safe, effective, and scalable editing platforms.

Technological advancements in delivery systems, precision targeting, and off-target risk mitigation are expanding genome editing's therapeutic applicability. Integration with digital tools and AI-driven bioinformatics platforms is improving target discovery, optimizing design workflows, and accelerating preclinical development. In agriculture and food biotechnology, gene editing is applied to develop disease-resistant, high-yield crops, aligning with national food security and sustainability goals.

With cross-sector partnerships, increased R&D activity, and supportive policy frameworks, the Japan genome editing market is well-positioned to play a leading role in shaping the future of precision biotechnology. Strategic alliances, localized manufacturing, and a growing IP portfolio reinforce Japan's position as a key hub for genome editing innovation in therapeutic and non-therapeutic applications.

Japan Genome Editing Market Report Highlights:

• By technology, CRISPR/Cas9 dominated the Japan genome editing market with a market share of 44.14% in 2024. This dominance stems from CRISPR/Cas9's superior efficiency, precision, and cost-effectiveness in targeted genome modifications. Its widespread adoption across research institutes, biotech startups, and pharmaceutical companies reflects its ability to accelerate functional genomics studies, therapeutic development, and agricultural innovation. The relatively easier design and scalability of CRISPR/Cas9 tools make them the preferred choice for both in vitro and in vivo applications.
• By delivery method, in vivo genome editing led the market with a market share of 50.63% in 2024, driven by rising investments in gene therapy and regenerative medicine, especially for treating inherited diseases and cancers. Japan's advanced healthcare infrastructure and focus on curative therapies have fueled the development of novel delivery platforms, such as lipid nanoparticles and adeno-associated viral vectors (AAVs), enabling more effective gene transfer in living organisms. The ability to directly edit genes within the patient offers transformative potential and continues to attract clinical trial activity and investment.
• By application, genetic engineering emerged as the leading segment, with a market share of 73.16% in 2024, contributing the highest revenue share. The segment's growth is driven by Japan's commitment to disease modeling, therapeutic discovery, and functional genomics research. Genetic engineering is widely used across academia and industry to develop customized cell lines, engineer model organisms, and advance gene therapy pipelines. It also plays a crucial role in precision breeding for agriculture and aquaculture, which are strategic sectors in Japan's biotech innovation agenda.
• By mode, the contract segment held the largest share of 66.77% in 2024, as outsourcing genome editing services becomes increasingly common among biotech startups and research institutions. Contract service providers offer specialized expertise, infrastructure, and regulatory support, allowing innovators to reduce time-to-market and control development costs. Japan's strong contract research and manufacturing organization ecosystem supports gene editing across preclinical, clinical, and commercial phases.
• By end use, biotechnology and pharmaceutical companies dominated the Japan genome editing market with a share of 49.66% in 2024. These companies leverage genome editing to accelerate drug discovery, develop gene and cell therapies, and explore novel treatment modalities for complex diseases. With robust R&D pipelines and increasing government incentives, these end users are at the forefront of innovation. Collaborations with academic institutions and global biotech firms further strengthen their position, making them central players in the commercial Application of genome editing technologies.
• In January 2025, Takara?Bio USA Holdings, Inc. completed the acquisition of California?based Curio Bioscience, integrating its Trekker and Seeker spatial?biology platforms into its U.S. single?cell omics portfolio.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Technology Segment
  • 1.2.2. Method Segment
  • 1.2.3. Application Segment
  • 1.2.4. Mode Segment
  • 1.2.5. End-use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Japan Genome Editing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Japan Genome Editing Market: Technology Business Analysis

• 4.1. Technology Segment Dashboard
• 4.2. Japan Genome Editing Market Technology Movement Analysis
• 4.3. Japan Genome Editing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 4.4. CRISPR/Cas9
  • 4.4.1. CRISPR/Cas9 market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. TALENs/MegaTALs
  • 4.5.1. TALENS/MegaTALs market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. ZFN
  • 4.6.1. ZFN market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Meganucleases
  • 4.7.1. Meganucleases market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Japan Genome Editing Market: Delivery Method Business Analysis

• 5.1. Delivery Method Segment Dashboard
• 5.2. Japan Genome Editing Market Delivery Method Movement Analysis
• 5.3. Japan Genome Editing Market Size & Trend Analysis, by Delivery Method, 2021 to 2033 (USD Million)
• 5.4. Ex-vivo
  • 5.4.1. Ex-vivo market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. In- vivo
  • 5.5.1. In-Vivo market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Japan Genome Editing Market: Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Japan Genome Editing Market Application Movement Analysis
• 6.3. Japan Genome Editing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Genetic Engineering
  • 6.4.1. Genetic Engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Cell line engineering
    • 6.4.2.1. Cell line engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Animal genetic engineering
    • 6.4.3.1. Animal genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Plant genetic engineering
    • 6.4.4.1. Plant genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.5. Others
    • 6.4.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Clinical Applications
  • 6.5.1. Clinical Applications market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.2. Therapy Development
    • 6.5.2.1. Therapy Development market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.3. Diagnostics Development
    • 6.5.3.1. Diagnostics Development market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Japan Genome Editing Market: Mode Business Analysis

• 7.1. Mode Segment Dashboard
• 7.2. Japan Genome Editing Market Mode Movement Analysis
• 7.3. Japan Genome Editing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
• 7.4. Contract
  • 7.4.1. Contract market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. In- house
  • 7.5.1. In-house market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Japan Genome Editing Market: End Use Estimates & Trend Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Japan Genome Editing Market End Use Movement Analysis
• 8.3. Japan Genome Editing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.4. Biotechnology & Pharmaceutical Companies
  • 8.4.1. Biotechnology & pharmaceutical companies market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Academic & Research Institutes
  • 8.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Contract Research Organizations
  • 8.6.1. Contract research organizations market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Merck KGaA
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Takara Bio Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Revvity, Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Danaher Corporation
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. GenScript
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. New England Biolabs
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Lonza
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Thermo Fisher Scientific, Inc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Charles River Laboratories
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Eurofins Scientific
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Japan Genome editing Market, By technology, 2021 - 2033 (USD Million)
• Table 5 Japan Genome editing Market, By delivery method, 2021 - 2033 (USD Million)
• Table 6 Japan Genome editing Market, By application, 2021 - 2033 (USD Million)
• Table 7 Japan Genome editing Market, By mode, 2021 - 2033 (USD Million)
• Table 8 Japan Genome editing Market, By end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Japan genome editing market segmentation
• Fig. 2 Information procurement
• Fig. 3 Data analysis models
• Fig. 4 Market formulation and validation
• Fig. 5 Data validating & publishing
• Fig. 6 Market research process
• Fig. 7 Information procurement
• Fig. 8 Primary research
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Japan genome editing market: Technology outlook key takeaways
• Fig. 13 Japan genome editing market: Technology movement analysis
• Fig. 14 Japan CRISPR/Cas9 market, 2021 - 2033 (USD Million)
• Fig. 15 Japan TALENs/MegaTALs market, 2021 - 2033 (USD Million)
• Fig. 16 Japan ZFN market, 2021 - 2033 (USD Million)
• Fig. 17 Japan meganucleases market, 2021 - 2033 (USD Million)
• Fig. 18 Japan others market, 2021 - 2033 (USD Million)
• Fig. 19 Japan genome editing market: Delivery Method outlook and key takeaways
• Fig. 20 Japan genome editing market: Delivery Method movement analysis
• Fig. 21 Japan ex- vivo market, 2021 - 2033 (USD Million)
• Fig. 22 Japan in- vivo market, 2021 - 2033 (USD Million)
• Fig. 23 Japan genome editing market: Application outlook and key takeaways
• Fig. 24 Japan genome editing market: Application movement analysis
• Fig. 25 Japan genetic engineering market, 2021 - 2033 (USD Million)
• Fig. 26 Japan cell line engineering market, 2021 - 2033 (USD Million)
• Fig. 27 Japan animal engineering market, 2021 - 2033 (USD Million)
• Fig. 28 Japan plant engineering market, 2021 - 2033 (USD Million)
• Fig. 29 Japan others market, 2021 - 2033 (USD Million)
• Fig. 30 Japan clinical applications market, 2021 - 2033 (USD Million)
• Fig. 31 Japan diagnostics development market, 2021 - 2033 (USD Million)
• Fig. 32 Japan therapy development market, 2021 - 2033 (USD Million)
• Fig. 33 Japan genome editing market: Mode outlook and key takeaways
• Fig. 34 Japan genome editing market: Mode movement analysis
• Fig. 35 Japan contract market, 2021 - 2033 (USD Million)
• Fig. 36 Japan in- house market, 2021 - 2033 (USD Million)
• Fig. 37 Japan genome editing market: End use outlook and key takeaways
• Fig. 38 Japan genome editing market: End use movement analysis
• Fig. 39 Japan biotechnology & pharmaceutical companies market, 2021 - 2033 (USD Million)
• Fig. 40 Japan academic & research institutes market, 2021 - 2033 (USD Million)
• Fig. 41 Japan contract research organizations market, 2021 - 2033 (USD Million)